Liste des publications
Boisdron-Celle M, Capitain O, Metges JP et al.  WCGC GI Barcelone 2014 Poster PD 007.
 

Gamelin E, Boisdron-Celle M, Morel A. Oncologie (Springer Verlag-France) 16, 96-102 (2014).

 

31 - Dihydropyrimidine dehydrogenase and fluoropyrimidines: a review of current dose adaptation practices and the impact on the future of personalized medicine using 5-fluorouracile.

Boisdron-Celle M, Biason P, Gamelin E et al. Colorectal Cancer 2(6), 1-11 (2013).

 

30 - 5-fluorouracile: MSI, phamacocinétique, DPD, TYMS et MTHFR. Chapitre 6 du livre «Médecine Personnalisée en Cancérologie Digestive, vers un traitement à la carte» édition 2013 Springer 

Boisdron-Celle M, Guérin-Meyer V, Capitain O.

 

29 - Actualités en Pharmacovigilance: 5-Fluorouracile et capécitabine: éviter les toxicités potentiellement mortelles."Le dépistage prèthérapeutique du déficit en DPD doit devenir une nécessité..."

Edition n°50 d'avril 2013 du Bulletin d'information du Centre Régional de Pharmacovigilance d'Angers

 

28 - Prevention of 5-FU-induced health-threatening toxicity by pre-therapeutic DPD deficiency screening: Medical and economic assessment of a multiparametric approach.

Boisdron-Celle M, Capitain O, Farou R at al. Asco Annual Meeting 2013 Abstract 3601

 

27 - Individual Fluorouracil Dose Adjustment in FOLFOX Based on Pharmacokinetic Follow-Up Compared with Conventional BSA Dosing: A Phase 2, proof-of-concept study.

Capitain O, Asevoaia A, Boisdron-Celle M et al. Clin Col Cancer. 11(4), 263-267 (2012).

 

26 - Pharmacokinetic adaptation of 5-fluorouracil: where are we and where are we going?

Boisdron-Celle M. Pharmacogenomics. Editorial. 13(13), 1437-1439 (2012).

 

25 - Therapeutic drug monitoring of 5-fluorouracil after its administration in high-dose protocols

Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique.

Boisdron-Celle M, Le Guellec C. Therapie. 65(3), 171-176 (2010).

 

24 - Lethal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutation
Mounier-Boutoille H, Boisdron-Celle M, Cauchin E et al. Br J Clin Pharmacol. 70(2), 280-283 (2010).

 

23 - Dihydropyrimidine dehydrogenase deficiency and toxicity to fluoropyrimidine. 
Boisdron-Celle M, Morel A, Gamelin E
Ann Biol Clin. 68(1), 27-32 (2010).

 

22 - Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer
Beumer JH, Boisdron-Celle M, Clarke W et al. 
Ther Drug Monit. 31(6), 688-694 (2009).

 

21 - Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients.
Rouits E, Charasson V, Pétain A et al. Br J Cancer. 99(8), 1239-1245 (2008).

 

20 - Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.
Gamelin E, Delva R, Jacob J et al. J Clin Oncol. 26(13), 2099-2105 (2008).

 

19 - The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer.
Capitain O, Boisdron-Celle M, Poirier AL et al. Pharmacogenomics J. 8(4), 256-267 (2008).

 

18 - A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient.
Blasco H, Boisdron-Celle M, Bougnoux P et al.
 Br J Clin Pharmacol. 65(6), 966-970 (2008).

 

17 - Pharmacogenetics of anti-cancer drugs.

Gamelin E, Boisdron-Celle M, Morel A et al. Ann Pharm Fr. 65(6), 390-401 (2007). 

 

16 - Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy.
Beneton M, Chapet S, Blasco H et al.
 
Br J Clin Pharmacol. 64(5), 613-621 (2007).

 

15 - Detection of dihydropyrimidine dehydrogenase deficiency before treatment by fluoropyrimidines.
Gamelin E, Boisdron-Celle M, Morel A.
 
Therapie. 62(2), 99-103 (2007).

 

14 - 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency.

Boisdron-Celle M, Remaud G, Traore S et al. Cancer Lett. 249(2), 271-282 (2007). 


13 - Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma
.
Morel A, Boisdron-Celle M, Fey L et al.
 Clin Biochem. 40(1-2), 11-17 (2007).

 

12 - Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance.

Morel A, Boisdron-Celle M, Fey L et al. Mol Cancer Ther. 5(11), 2895-2904 (2006).


11 - An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice.
Remaud G, Boisdron-Celle M, Hameline C et al
J Chromatogr B Analyt Technol Biomed Life Sci. 823(2), 98-107 (2005).

10 - Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences
.
Boisdron-Celle M, Craipeau C, Brienza S et al. 
Cancer Chemother Pharmacol. 49(3), 235-243 (2002). 

9 - Pharmacokinetic monitoring.
Boisdron-Celle M, Boulanger N, Gamelin E
Bull Cancer. 87(1), 86-92 (2000). 

8 - Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage.
Gamelin E, Boisdron-Celle M, Guérin-Meyer V et al. J Clin Oncol. 17(4), 1105-1110 (1999).

7 - Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer--status of the art.
Gamelin E, Boisdron-Celle M.
 
Crit Rev Oncol Hematol. 30(1), 71-79 (1999). 

6 - Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients
.
Gamelin E, Boisdron-Celle M, Delva R et al.
 J Clin Oncol. 16(4), 1470-1478 (1998).

 

5 - A simple chromatographic method for the analysis of pyrimidines and their dihydrogenated metabolites.

Gamelin E, Boisdron-Celle M, Larra F, Robert J. J Liqu Chrom Rel Tech 20(19), 3155-3172 (1997).

 

4 - Rapid and sensitive high-performance liquid chromatographic analysis of halogenopyrimidines in plasma.
Gamelin E, Boisdron-Celle M, Turcant A et alJ Chromatogr B Biomed Sci Appl. 695(2), 409-416 (1997).

3 - Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients.
Gamelin E, Bouil AL, Boisdron-Celle M et al. Clin Cancer Res. 3(6), 891-899 (1997).

2 - Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU.
Gamelin EC, Danquechin-Dorval EM, Dumesnil YF et al. 
Cancer. 77(3), 441-451 (1996).

1 - Individual dose adjustment in anticancer chemotherapy.

Gamelin E, Boisdron-Celle M. Rev Med Interne. 17(7), 529-533 (1996).